Related references
Note: Only part of the references are listed.Long-term outcomes of intravitreal ranibizumab for neovascular age-related macular degeneration in a well defined region of the UK
Miranda Buckle et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2016)
UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12
Aaron Y. Lee et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2015)
Two-Year Outcomes of Treat and Extend Intravitreal Therapy for Neovascular Age-Related Macular Degeneration
Jennifer J. Arnold et al.
OPHTHALMOLOGY (2015)
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
Frank G. Holz et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2015)
One-year outcome of ranibizumab for neovascular age-related macular degeneration: a thorough analysis in a real-world clinical setting
Andrea Gabai et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2014)
The Neovascular Age-Related Macular Degeneration Database: Multicenter Study of 92 976 Ranibizumab Injections
Adnan Tufail et al.
OPHTHALMOLOGY (2014)
The Neovascular Age-Related Macular Degeneration Database Report 2: Incidence, Management, and Visual Outcomes of Second Treated Eyes
Javier Zarranz-Ventura et al.
OPHTHALMOLOGY (2014)
A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration
Ilse Krebs et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2013)
Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?
A. H. Ross et al.
EYE (2013)
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
Usha Chakravarthy et al.
LANCET (2013)
Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial
Laurent Kodjikian et al.
OPHTHALMOLOGY (2013)
Prospective Audit of Exudative Age-Related Macular Degeneration: 12-Month Outcomes in Treatment-Naive Eyes
Mark C. Gillies et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2013)
Time Trends in the Incidence and Causes of Blindness in Israel
Alon Skaat et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2012)
Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010
Sara Brandi Bloch et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2012)
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
Daniel F. Martin et al.
OPHTHALMOLOGY (2012)
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Usha Chakravarthy et al.
OPHTHALMOLOGY (2012)
Myositis Ossificans
Deborah A. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Evaluation of Injection Frequency and Visual Acuity Outcomes for Ranibizumab Monotherapy in Exudative Age-related Macular Degeneration
Hajir Dadgostar et al.
OPHTHALMOLOGY (2009)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
